Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/15/2025

Anticoagulation Therapy for Arterial Thrombosis

Introduction to DOACs in Arterial Thrombosis

  • For patients with peripheral arterial disease and COVID-19 receiving therapeutic anticoagulation, individualized decisions regarding antiplatelet therapy continuation are recommended, considering drug interactions between DOACs and COVID-19 treatments, especially protease inhibitors, due to cytochrome P450 3A4 and P-glycoprotein interactions, as suggested by the European Society of Cardiology 1
  • The American Society of Clinical Oncology recommends considering drug interactions and bleeding risk, especially with GI or GU malignancies, when using DOACs in cancer patients, highlighting the importance of careful patient selection and monitoring 2

Safety Considerations for DOACs

  • Particular caution is advised when using DOACs with cancer therapies, including tyrosine kinase inhibitors, due to potential drug interactions, emphasizing the need for thorough evaluation of concomitant medications 3
  • Patients with severe renal impairment may require dose adjustments or may be contraindicated for DOAC use, while those with active cancer may require special considerations, though recent evidence supports DOAC use in many cancer patients, as stated by the American Society of Clinical Oncology and the American College of Chest Physicians 4, 5

Patient-Specific Factors in DOAC Use

  • The European Society of Cardiology suggests that patients with a history of arterial thrombosis should avoid DOACs, and instead use traditional anticoagulation or antiplatelet therapy, due to increased risk of recurrent arterial thrombosis 1
  • For patients with antiphospholipid syndrome, especially those with triple-positive APS, DOACs should be avoided due to increased risk of recurrent arterial thrombosis, highlighting the importance of careful patient selection and monitoring 1

DOAC Classification and Mechanism

  • The following table summarizes the DOACs classification:
DOAC Target
Apixaban Factor Xa
Edoxaban Factor Xa
Rivaroxaban Factor Xa
Dabigatran Thrombin

4, 6

Efficacy and Safety of DOACs

  • DOACs offer a convenient treatment option for Venous Thromboembolism (VTE) with fixed dosing, eliminating the need for regular laboratory monitoring, as recommended by the American College of Chest Physicians and the American College of Cardiology, with a predictable pharmacokinetics and pharmacodynamics profile 4, 6, 5, 7
  • DOACs are at least as effective as VKAs in preventing recurrent VTE, with a lower risk of major bleeding, including intracranial hemorrhage, and apixaban may have a lower bleeding risk profile compared to other agents in the class, as supported by the American College of Cardiology and the American College of Chest Physicians 4, 6, 5, 7
  • Current clinical guidelines prefer DOACs over VKAs for most patients with VTE due to their convenience, efficacy, and safety profile, with the American College of Cardiology recommending DOACs as a first-line treatment option for patients with non-valvular atrial fibrillation at high risk of stroke 4, 6, 5, 7

Monitoring and Reversal of DOACs

  • Routine coagulation monitoring is generally not required for DOACs, but conventional tests and specialized tests may be used in specific situations, and DOACs may be continued or discontinued depending on the bleeding risk for patients requiring procedures, as stated by the American College of Chest Physicians 8
  • Specific reversal agents are available, including idarucizumab and andexanet alfa, for management of bleeding complications associated with DOAC use, highlighting the importance of prompt recognition and treatment of bleeding events 9, 10, 8

REFERENCES

8

Reversal of Direct Oral Anticoagulants [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

10

drug interactions affecting oral anticoagulant use. [LINK]

Circulation: Arrhythmia and Electrophysiology, 2022